Compare SFL & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFL | ALMR |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2004 | 2026 |
| Metric | SFL | ALMR |
|---|---|---|
| Price | $11.24 | $23.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 382.4K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | ★ 7.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.73 | $21.58 |
| 52 Week High | $12.94 | $29.43 |
| Indicator | SFL | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 49.80 |
| Support Level | $10.89 | N/A |
| Resistance Level | $11.52 | $29.06 |
| Average True Range (ATR) | 0.28 | 1.96 |
| MACD | 0.08 | -0.29 |
| Stochastic Oscillator | 87.64 | 0.17 |
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.